Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CDA | P32320 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | TK2 | O00142 | 2/20 | 0.32 |
| ▸ | PYGM | P11217 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685237 | 0.86 | CDA (0.43) | MAPTCDATK2PYGM | |
| SCHEMBL31685497 | 0.82 | OGA (0.35) | MAPTCDAMEN1KMT2ALGALS8 | |
| SCHEMBL31685308 | 0.81 | LMNA (0.36) | MAPTCDAMEN1KMT2ALGALS8 | |
| SCHEMBL31685759 | 0.81 | LMNA (0.34) | MAPTCDAMEN1KMT2ALGALS8 | |
| SCHEMBL31685165 | 0.80 | ADORA1 (0.39) | — | |
| SCHEMBL31685351 | 0.78 | MEN1 (0.35) | MAPTCDAMEN1KMT2ALGALS8 | |
| SCHEMBL31685741 | 0.77 | LGALS8 (0.35) | MAPTCDAMEN1KMT2ALGALS8 | |
| SCHEMBL31685570 | 0.73 | LMNA (0.51) | MAPT | |
| SCHEMBL31685178 | 0.72 | UMPS (0.49) | — | |
| SCHEMBL31685516 | 0.72 | TK1 (0.43) | TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | MAPT 953/4885CDA 275/4885MEN1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.